Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02639182 · ClinicalTrials.gov registry record · Phase 2
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
A Phase 2 study, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 133
- Enrollment target
NCT02639182 is a Phase 2 study that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 133 participants.
The verdict
NCT02639182, a Phase 2 study, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 133 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the progression free survival (PFS), based on investigator radiologic review, of AGS-16C3F compared to axitinib in subjects with metastatic renal cell carcinoma.
Interventions
- DRUG Axitinib
- DRUG AGS-16C3F
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2016-05-03 |
| Est. Completion | 2020-10-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02639182
The ClinicalTrials.gov registry entry for NCT02639182 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Axitinib is the first listed.
NCT02639182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02639182 about?
NCT02639182 is a clinical study titled "A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma". The purpose of this study was to evaluate the progression free survival (PFS), based on investigator radiologic review, of AGS-16C3F compared to axitinib in subjects with metastatic renal cell carcinoma.
What is the current status of trial NCT02639182?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 133 participants. The study started on 2016-05-03. Estimated completion is 2020-10-02.
What interventions are being tested in trial NCT02639182?
The interventions under investigation include: Axitinib (DRUG), AGS-16C3F (DRUG).
Who is sponsoring clinical trial NCT02639182?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.